Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004022 · ClinicalTrials.gov registry record · Phase 2
Biological Therapy Following Surgery in Treating Patients With Stage III or Stage IV Melanoma
A Phase 2 study, sponsored by Barbara Ann Karmanos Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00004022: Completed Phase 2 study, sponsored by Barbara Ann Karmanos Cancer Institute.
NCT00004022 is a Phase 2 study that has completed, run by Barbara Ann Karmanos Cancer Institute. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004022, a Phase 2 study, has completed, sponsored by Barbara Ann Karmanos Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Combining different types of biological therapies may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of biological therapy following surgery in treating patients who have stage III or stage IV melanoma.
Interventions
- BIOLOGICAL therapeutic autologous lymphocytes
- BIOLOGICAL aldesleukin
- BIOLOGICAL autologous tumor cell vaccine
- PROCEDURE surgical procedure
- BIOLOGICAL muromonab-CD3
Trial Details
| Field | Value |
|---|---|
| Start Date | 1997-06 |
| Est. Completion | 2004-01 |
| Phase | Phase 2 |
What the finished NCT00004022 record still lists
NCT00004022 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 5 interventions - of which therapeutic autologous lymphocytes is the first listed.
NCT00004022 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00004022 about?
NCT00004022 is a clinical study titled "Biological Therapy Following Surgery in Treating Patients With Stage III or Stage IV Melanoma". RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Combining different types of biological therapies may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of biological therapy following surgery in treating p...
What is the current status of trial NCT00004022?
This trial is currently completed. It is a Phase 2 study. The study started on 1997-06. Estimated completion is 2004-01.
What interventions are being tested in trial NCT00004022?
The interventions under investigation include: therapeutic autologous lymphocytes (BIOLOGICAL), aldesleukin (BIOLOGICAL), autologous tumor cell vaccine (BIOLOGICAL), surgical procedure (PROCEDURE), muromonab-CD3 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00004022?
This trial is sponsored by Barbara Ann Karmanos Cancer Institute, which has 139 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia